Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming

Science Translational Medicine

Volumn 8, Issue 333, 2016, Pages

  Zimmer, Sebastian ^a   Grebe, Alena ^a   Bakke, Siril S ^a,b,c   Bode, Niklas ^a   Halvorsen, Bente ^d   Ulas, Thomas ^e   Skjelland, Mona ^d   De Nardo, Dominic ^a,f,g   Labzin, Larisa I ^a   Kerksiek, Anja ^a   Hempel, Chris ^h   Heneka, Michael T ^a   Hawxhurst, Victoria ⁱ   Fitzgerald, Michael L ⁱ   Trebicka, Jonel ^a,j   Björkhem, Ingemar ^k   Gustafsson, Jan Åke ^l   Westerterp, Marit ^m   Tall, Alan R ^m   Wright, Samuel D ⁿ   Espevik, Terje ^c   Schultze, Joachim L ^b,e   Nickenig, Georg ^a   Lütjohann, Dieter ^a   Latz, Eicke ^a,b,c,o   more..

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF BONN   (Germany)

^f WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h Addi and Cassi Fund   (United States)

ⁱ Center for Systems Biology   (United States)

^j UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^k KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^l University of Houston   (United States)

^m Och Spine at New York Presbyterian Hospitals   (United States)

ⁿ CSL Behring LLC   (United States)

^o UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CHOLESTEROL; LIVER X RECEPTOR; OXYSTEROL; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; CRYSTALLIZATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PLAQUE, ATHEROSCLEROTIC; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ATHEROSCLEROSIS; BETA-CYCLODEXTRINS; BIOLOGICAL TRANSPORT; CHOLESTEROL; CRYSTALLIZATION; GENE EXPRESSION REGULATION; HUMANS; LIVER X RECEPTORS; MACROPHAGES; MICE; PLAQUE, ATHEROSCLEROTIC;

EID: 84963632271     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aad6100     Document Type: Article

References (57)

1. J. G. Robinson, M. Farnier, M. Krempf, J. Bergeron, G. Luc, M. Averna, E. S. Stroes, G. Langslet, F. J. Raal, M. E. Shahawy, M. J. Koren, N. E. Lepor, C. Lorenzato, R. Pordy, U. Chaudhari, J. J. P. Kastelein; ODYSSEY LONG TERM Investigators, Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372, 1489-1499 (2015).
2. M. S. Sabatine, R. P. Giugliano, S. D. Wiviott, F. J. Raal, D. J. Blom, J. Robinson, C. M. Ballantyne, R. Somaratne, J. Legg, S. M. Wasserman, R. Scott, M. J. Koren, E. A. Stein; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators, Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372, 1500-1509 (2015).
3. Task Force Members, G. Montalescot, U. Sechtem, S. Achenbach, F. Andreotti, C. Arden, A. Budaj, R. Bugiardini, F. Crea, T. Cuisset, C. Di Mario, J. R. Ferreira, B. J. Gersh, A. K. Gitt, J. S. Hulot, N. Marx, L. H. Opie, M. Pfisterer, E. Prescott, F. Ruschitzka, M. Sabaté, R. Senior, D. P. Taggart, E. E. van der Wall, C. J. M. Vrints; ESC Committee for Practice Guidelines (CPG), J. L. Zamorano, S. Achenbach, H. Baumgartner, J. J. Bax, H. Bueno, V. Dean, C. Deaton, C. Erol, R. Fagard, R. Ferrari, D. Hasdai, A. W. Hoes, P. Kirchhof, J. Knuuti, P. Kohl, P. Lancellotti, A. Linhart, P. Nihoyannopoulos, M. F. Piepoli, P. Ponikowski, P. A. Sirnes, J. L. Tamargo, M. Tendera, A. Torbicki, W. Wijns, S. Windecker; Document Reviewers, J. Knuuti, M. Valgimigli, H. Bueno, M. J. Claeys, N. Donner-Banzhoff, C. Erol, H. Frank, C. Funck-Brentano, O. Gaemperli, J. R. Gonzalez-Juanatey, M. Hamilos, D. Hasdai, S. Husted, S. K. James, K. Kervinen, P. Kolh, S. D. Kristensen, P. Lancellotti, A. P. Maggioni, M. F. Piepoli, A. R. Pries, F. Romeo, L. Rydén, M. L. Simoons, P. A. Sirnes, P. G. Steg, A. Timmis, W. Wijns, S. Windecker, A. Yildirir, J. L. Zamorano, 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur. Heart J. 34, 2949-3003 (2013).
4. F. J. Sheedy, A. Grebe, K. J. Rayner, P. Kalantari, B. Ramkhelawon, S. B. Carpenter, C. E. Becker, H. N. Ediriweera, A. E. Mullick, D. T. Golenbock, L. M. Stuart, E. Latz, K. A. Fitzgerald, K. J. Moore, CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat. Immunol. 14, 812-820 (2013).
5. P. Duewell, H. Kono, K. J. Rayner, C. M. Sirois, G. Vladimer, F. G. Bauernfeind, G. S. Abela, L. Franchi, G. Nuñez, M. Schnurr, T. Espevik, E. Lien, K. A. Fitzgerald, K. L. Rock, K. J. Moore, S. D. Wright, V. Hornung, E. Latz, NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357-1361 (2010).
6. P. M. Ridker, T. Thuren, A. Zalewski, P. Libby, Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am. Heart J. 162, 597-605 (2011).
7. A. Warnatsch, M. Ioannou, Q. Wang, V. Papayannopoulos, Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. Science 349, 316-320 (2015).
8. S. Nymo, N. Niyonzima, T. Espevik, T. E. Mollnes, Cholesterol crystal-induced endothelial cell activation is complement-dependent and mediated by TNF. Immunobiology 219, 786-792 (2014).
9. E. O. Samstad, N. Niyonzima, S. Nymo, M. H. Aune, L. Ryan, S. S. Bakke, K. T. Lappegård, O.-L. Brekke, J. D. Lambris, J. K. Damås, E. Latz, T. E. Mollnes, T. Espevik, Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release. J. Immunol. 192, 2837-2845 (2014).
10. R. Kiyotake, M. Oh-Hora, E. Ishikawa, T. Miyamoto, T. Ishibashi, S. Yamasaki, Human mincle binds to cholesterol crystals and triggers innate immune responses. J. Biol. Chem. 290, 25322-25332 (2015).
11. K. J. Rayner, C. C. Esau, F. N. Hussain, A. L. McDaniel, S. M. Marshall, J. M. van Gils, T. D. Ray, F. J. Sheedy, L. Goedeke, X. Liu, O. G. Khatsenko, V. Kaimal, C. J. Lees, C. Fernandez-Hernando, E. A. Fisher, R. E. Temel, K. J. Moore, Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 478, 404-407 (2011).
12. S. Gould, R. C. Scott, 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): A toxicology review. Food Chem. Toxicol. 43, 1451-1459 (2005).
13. T. Loftsson, P. Jarho, M. Másson, T. Järvinen, Cyclodextrins in drug delivery. Expert Opin. Drug Deliv. 2, 335-351 (2005).
14. S. M. Liu, A. Cogny, M. Kockx, R. T. Dean, K. Gaus, W. Jessup, L. Kritharides, Cyclodextrins differentially mobilize free and esterified cholesterol from primary human foam cell macrophages. J. Lipid Res. 44, 1156-1166 (2003).
15. L. Kritharides, M. Kus, A. J. Brown, W. Jessup, R. T. Dean, Hydroxypropyl-β-cyclodextrin-mediated efflux of 7-ketocholesterol from macrophage foam cells. J. Biol. Chem. 271, 27450-27455 (1996).
16. V. M. Atger, M. de la Llera Moya, G. W. Stoudt, W. V. Rodrigueza, M. C. Phillips, G. H. Rothblat, Cyclodextrins as catalysts for the removal of cholesterol from macrophage foam cells. J. Clin. Invest. 99, 773-780 (1997).
17. D. S. Mackay, P. J. H. Jones, Plasma noncholesterol sterols: Current uses, potential and need for standardization. Curr. Opin. Lipidol. 23, 241-247 (2012).
18. G. S. Getz, C. A. Reardon, Animal models of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 32, 1104-1115 (2012).
19. B. Hewing, E. A. Fisher, Preclinical mouse models and methods for the discovery of the causes and treatments of atherosclerosis. Expert Opin. Drug Discov. 7, 207-216 (2012).
20. K. J. Rayner, F. J. Sheedy, C. C. Esau, F. N. Hussain, R. E. Temel, S. Parathath, J. M. van Gils, A. J. Rayner, A. N. Chang, Y. Suarez, C. Fernandez-Hernando, E. A. Fisher, K. J. Moore, Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J. Clin. Invest. 121, 2921-2931 (2011).
21. I. Tabas, Consequences of cellular cholesterol accumulation: Basic concepts and physiological implications. J. Clin. Invest. 110, 905-911 (2002).
22. J. J. Repa, D. J. Mangelsdorf, The liver X receptor gene team: Potential new players in atherosclerosis. Nat. Med. 8, 1243-1248 (2002).
23. A. R. Tall, L. Yvan-Charvet, Cholesterol, inflammation and innate immunity. Nat. Rev. Immunol. 15, 104-116 (2015).
24. A. Reboldi, E. V. Dang, J. G. McDonald, G. Liang, D. W. Russell, J. G. Cyster, 25-Hydroxycholesterol suppresses interleukin-1-driven inflammation downstream of type I interferon. Science 345, 679-684 (2014).
25. A. V. Khera, M. Cuchel, M. de la Llera-Moya, A. Rodrigues, M. F. Burke, K. Jafri, B. C. French, J. A. Phillips, M. L. Mucksavage, R. L. Wilensky, E. R. Mohler, G. H. Rothblat, D. J. Rader, Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364, 127-135 (2011).
26. A. Rohatgi, A. Khera, J. D. Berry, E. G. Givens, C. R. Ayers, K. E. Wedin, I. J. Neeland, I. S. Yuhanna, D. R. Rader, J. A. de Lemos, P. W. Shaul, HDL cholesterol efflux capacity and incident cardiovascular events. N. Engl. J. Med. 371, 2383-2393 (2014).
27. D. J. Rader, E. Puré, Lipoproteins, macrophage function, and atherosclerosis: Beyond the foam cell? Cell Metab. 1, 223-230 (2005).
28. B. A. Janowski, P. J. Willy, T. R. Devi, J. R. Falck, D. J. Mangelsdorf, An oxysterol signalling pathway mediated by the nuclear receptor LXRα. Nature 383, 728-731 (1996).
29. A. Subramanian, P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, A. Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander, J. P. Mesirov, Gene set enrichment analysis: A knowledgebased approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 102, 15545-15550 (2005).
30. S. Heinz, C. Benner, N. Spann, E. Bertolino, Y. C. Lin, P. Laslo, J. X. Cheng, C. Murre, H. Singh, C. K. Glass, Simple combinations of lineage-determining transcription factors prime cisregulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576-589 (2010).
31. J. J. Repa, S. D. Turley, J.-M. A. Lobaccaro, J. Medina, L. Li, K. Lustig, B. Shan, R. A. Heyman, J. M. Dietschy, D. J. Mangelsdorf, Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289, 1524-1529 (2000).
32. B. Liu, H. Li, J. J. Repa, S. D. Turley, J. M. Dietschy, Genetic variations and treatments that affect the lifespan of the NPC1 mouse. J. Lipid Res. 49, 663-669 (2008).
33. -/- mice without carrying cholesterol through the bloodstream. J. Lipid Res. 53, 2331-2342 (2012).
34. A. Mayor, F. Martinon, T. De Smedt, V. Pétrilli, J. Tschopp, A crucial function of SGT1 and HSP90 in inflammasome activity links mammalian and plant innate immune responses. Nat. Immunol. 8, 497-503 (2007).
35. A. Castrillo, S. B. Joseph, S. A. Vaidya, M. Haberland, A. M. Fogelman, G. Cheng, P. Tontonoz, Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol. Cell 12, 805-816 (2003).
36. K. R. Feingold, C. Grunfeld, The acute phase response inhibits reverse cholesterol transport. J. Lipid Res. 51, 682-684 (2010).
37. D. De Nardo, L. I. Labzin, H. Kono, R. Seki, S. V. Schmidt, M. Beyer, D. Xu, S. Zimmer, C. Lahrmann, F. A. Schildberg, J. Vogelhuber, M. Kraut, T. Ulas, A. Kerksiek, W. Krebs, N. Bode, A. Grebe, M. L. Fitzgerald, N. J. Hernandez, B. R. G. Williams, P. Knolle, M. Kneilling, M. Röcken, D. Lütjohann, S. D. Wright, J. L. Schultze, E. Latz, High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat. Immunol. 15, 152-160 (2014).
38. -/- mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells. Arterioscler. Thromb. Vasc. Biol. 34, 279-284 (2014).
39. S. B. Joseph, E. McKilligin, L. Pei, M. A. Watson, A. R. Collins, B. A. Laffitte, M. Chen, G. Noh, J. Goodman, G. N. Hagger, J. Tran, T. K. Tippin, X. Wang, A. J. Lusis, W. A. Hsueh, R. E. Law, J. L. Collins, T. M. Willson, P. Tontonoz, Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. U.S.A. 99, 7604-7609 (2002).
40. J. E. Feig, I. Pineda-Torra, M. Sanson, M. N. Bradley, Y. Vengrenyuk, D. Bogunovic, E. L. Gautier, D. Rubinstein, C. Hong, J. Liu, C. Wu, N. van Rooijen, N. Bhardwaj, M. Garabedian, P. Tontonoz, E. A. Fisher, LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. J. Clin. Invest. 120, 4415-4424 (2010).
41. X. Li, V. Yeh, V. Molteni, Liver X receptor modulators: A review of recently patented compounds (2007-2009). Expert Opin. Ther. Pat. 20, 535-562 (2010).
42. V. Hornung, F. Bauernfeind, A. Halle, E. O. Samstad, H. Kono, K. L. Rock, K. A. Fitzgerald, E. Latz, Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9, 847-856 (2008).
43. S. Wassmann, A. T. Bäumer, K. Strehlow, M. van Eickels, C. Grohé, K. Ahlbory, R. Rösen, M. Böhm, G. Nickenig, Endothelial dysfunction and oxidative stress during estrogen deficiency in spontaneously hypertensive rats. Circulation 103, 435-441 (2001).
44. D. Lütjohann, C. Hahn, W. Prange, T. Sudhop, M. Axelson, T. Sauerbruch, K. von Bergmann, C. Reichel, Influence of rifampin on serum markers of cholesterol and bile acid synthesis in men. Int. J. Clin. Pharmacol. Ther. 42, 307-313 (2004).
45. D. Lütjohann, A. Brzezinka, E. Barth, D. Abramowski, M. Staufenbiel, K. von Bergmann, K. Beyreuther, G. Multhaup, T. A. Bayer, Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain. J. Lipid Res. 43, 1078-1085 (2002).
46. S. Zimmer, M. Steinmetz, T. Asdonk, I. Motz, C. Coch, E. Hartmann, W. Barchet, S. Wassmann, G. Hartmann, G. Nickenig, Activation of endothelial toll-like receptor 3 impairs endothelial function. Circ. Res. 108, 1358-1366 (2011).
47. J. Spandl, D. J. White, J. Peychl, C. Thiele, Live cell multicolor imaging of lipid droplets with a new dye, LD540. Traffic 10, 1579-1584 (2009).
48. D. Lütjohann, M. Stroick, T. Bertsch, S. Kühl, B. Lindenthal, K. Thelen, U. Andersson, I. Björkhem, K. von Bergmann, K. Fassbender, High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. Steroids 69, 431-438 (2004).
49. D. Lütjohann, O. Breuer, G. Ahlborg, I. Nennesmo, A. Sidén, U. Diczfalusy, I. Björkhem, Cholesterol homeostasis in human brain: Evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc. Natl. Acad. Sci. U.S.A. 93, 9799-9804 (1996).
50. S. Maere, K. Heymans, M. Kuiper, BiNGO: A Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 21, 3448-3449 (2005).
51. D. Merico, R. Isserlin, O. Stueker, A. Emili, G. D. Bader, Enrichment map: A network-based method for gene-set enrichment visualization and interpretation. PLOS One 5, e13984 (2010).
52. L. Oesper, D. Merico, R. Isserlin, G. D. Bader, WordCloud: A Cytoscape plugin to create a visual semantic summary of networks. Source Code Biol. Med. 6, 7 (2011).
53. T. G. Brott, J. L. Halperin, S. Abbara, J. M. Bacharach, J. D. Barr, R. L. Bush, C. U. Cates, M. A. Creager, S. B. Fowler, G. Friday, V. S. Hertzberg, E. B. McIff, W. S. Moore, P. D. Panagos, T. S. Riles, R. H. Rosenwasser, A. J. Taylor, 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Circulation 124, e54-e130 (2011).
54. D. S. Mackay, P. J. H. Jones, S. B. Myrie, J. Plat, D. Lütjohann, Methodological considerations for the harmonization of non-cholesterol sterol bio-analysis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 957, 116-122 (2014).
55. P. Pehkonen, L Welter-Stahl, J. Diwo, J. Ryynänen, A. Wienecke-Baldacchino, S. Heikkinen, E. Treuter, K. R. Steffensen, C. Carlberg, Genome-wide landscape of liver X receptor chromatin binding and gene regulation in human macrophages. BMC Genomics 13, 50 (2012).
56. E. B. Mathiesen, K. H. Bønaa, O. Joakimsen, Echolucent plaques are associated with high risk of ischemic cerebrovascular events in carotid stenosis: The tromsø study. Circulation 103, 2171-2175 (2001).
57. P. S. Olofsson, K Jatta, D. Wågsäter, S. Gredmark, U. Hedin, G. Paulsson-Berne, C Söderberg-Nauclér, G. K. Hansson, A. Sirsjö, The antiviral cytomegalovirus inducible gene 5/viperin is expressed in atherosclerosis and regulated by proinflammatory agents. Arterioscler. Thromb. Vasc. Biol. 25, e113-e116 (2005).